Tudor Investment Corp ET AL Trims Stock Position in Guardant Health, Inc. (NASDAQ:GH)

Tudor Investment Corp ET AL decreased its position in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) by 93.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 27,839 shares of the company's stock after selling 370,036 shares during the period. Tudor Investment Corp ET AL's holdings in Guardant Health were worth $850,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. R Squared Ltd acquired a new position in Guardant Health during the fourth quarter valued at approximately $26,000. SBI Securities Co. Ltd. acquired a new position in shares of Guardant Health in the 4th quarter valued at $43,000. Kimelman & Baird LLC acquired a new position in shares of Guardant Health in the 4th quarter valued at $58,000. NewEdge Advisors LLC increased its position in shares of Guardant Health by 13.5% in the 4th quarter. NewEdge Advisors LLC now owns 1,929 shares of the company's stock valued at $59,000 after buying an additional 230 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new stake in Guardant Health during the 4th quarter worth $80,000. Institutional investors own 92.60% of the company's stock.

Insiders Place Their Bets

In other Guardant Health news, CEO Amirali Talasaz sold 106,784 shares of the business's stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $49.01, for a total value of $5,233,483.84. Following the completion of the sale, the chief executive officer now owns 2,202,672 shares in the company, valued at approximately $107,952,954.72. The trade was a 4.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 107,132 shares of company stock valued at $5,249,355 over the last quarter. 5.50% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms recently commented on GH. UBS Group boosted their price objective on shares of Guardant Health from $65.00 to $70.00 and gave the company a "buy" rating in a research report on Thursday, May 1st. Scotiabank reaffirmed an "outperform" rating on shares of Guardant Health in a research report on Monday. Raymond James reissued an "outperform" rating and issued a $59.00 target price (up previously from $39.00) on shares of Guardant Health in a research report on Friday, February 21st. Morgan Stanley upped their price target on Guardant Health from $42.00 to $52.00 and gave the stock an "overweight" rating in a research report on Thursday, March 6th. Finally, Mizuho began coverage on shares of Guardant Health in a report on Thursday, April 10th. They issued an "outperform" rating and a $55.00 price objective on the stock. Twenty-one analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $52.32.

Guardant Health Trading Up 0.1 %

Shares of NASDAQ GH traded up $0.04 during midday trading on Friday, hitting $41.72. 2,781,560 shares of the company's stock were exchanged, compared to its average volume of 2,229,071. Guardant Health, Inc. has a 12-month low of $20.14 and a 12-month high of $52.92. The company has a market cap of $5.17 billion, a price-to-earnings ratio of -11.72 and a beta of 1.49. The business's fifty day moving average price is $43.72 and its two-hundred day moving average price is $38.84.

Guardant Health (NASDAQ:GH - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.57) by $0.08. The company had revenue of $203.47 million during the quarter, compared to the consensus estimate of $189.91 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The firm's revenue was up 20.8% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.46) EPS. Equities analysts expect that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.